AGIO 88.40 Agios Pharmaceuticals Inc $AGIO Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 10:12 AM

AGIO 88.40 Agios Pharmaceuticals Inc $AGIO Hit a 52 week high of 87.99 Closing the day 09:45 at 88.40 +1.53 +1.76% With a day low of 87.00 and a total volume of 61,098.

AGIO Recent Posts: http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/

AGIO Agios Pharmaceuticals Inc Recent Headline News

Jim Cramer Says to Buy Six Flags, Avoid SeaWorld Entertainment
at The Street - Wed Nov 12, 1:20PM CST
TheStreet's Jim Cramer says investors shouldn't be tricked by SeaWorld's attractive dividend yield. Instead, stick with Six Flags Entertainment.
SEAS: 16.81 (-0.04), SIX: 40.83 (-0.04), AGIO: 87.20 (+0.33)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 84.08 (-0.65), OREX: 5.97 (+0.13), PCMI: 8.80 (-0.10), CYAN: 6.20 (+0.22), ACHN: 14.27 (-0.58), TGTX: 14.36 (+0.33), AGIO: 87.20 (+0.33), LIOX: 5.40 (-0.03), SAJA: 5.90 (-0.35), PLNR: 7.16 (+0.01)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 175.14 (+1.46), SLXP: 96.55 (+1.00), ICPT: 160.25 (-2.71), IBB: 297.25 (+0.76), AGIO: 87.20 (+0.33)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST

AGIO: 87.20 (+0.33)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.47 (unch), ANET: 78.40 (+1.16), TKMR: 16.21 (+0.11), ORBC: 6.53 (-0.04), MDRX: 12.22 (+0.27), RMTI: 11.15 (-0.09), CTIC: 2.17 (-0.01), SHLD: 39.50 (+1.74), UBNT: 28.85 (-0.15), RIG: 27.03 (-0.05), KGC: 2.43 (-0.03), APT: 2.97 (-0.03), ANF: 29.68 (+0.33), MITK: 3.57 (-0.09), ZNGA: 2.91 (+0.10), CNET: 2.18 (+0.03), KING: 15.00 (+0.97), NETE: 1.39 (-0.01), SLXP: 96.55 (+1.00), RPRX: 10.11 (+0.68), NADL: 4.76 (-0.18), PGNX: 6.81 (+0.20), AVNR: 13.34 (+0.16), FSLR: 48.32 (-1.27), DVA: 77.13 (+0.41), NDLS: 24.09 (-0.05), ICPT: 160.25 (-2.71), AGIO: 87.20 (+0.33), PLNR: 7.16 (+0.01)

Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST

AGIO: 87.20 (+0.33)

Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 87.20 (+0.33)

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 87.20 (+0.33)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST

BAM: 50.01 (+0.15), ERF: 15.07 (-0.33), LXP: 11.08 (+0.09), PGEM: 13.00 (-0.02), CCOI: 35.76 (+0.84), TTI: 8.36 (-0.18), SJI: 57.94 (-0.12), NXST: 46.15 (+0.62), VSAT: 63.97 (-0.04), MT: 12.11 (+0.08), LXU: 33.28 (-0.08), HUM: 138.04 (+0.79), PGNX: 6.81 (+0.20), MHR: 4.74 (-0.07), CTB: 32.66 (+0.06), IDRA: 2.53 (-0.03), ISIS: 52.74 (+1.66), BPL: 80.20 (+0.74), SSP: 19.24 (+0.27), AGIO: 87.20 (+0.33), EBIX: 16.56 (unch)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 86.07 (-6.92), RNA: 11.73 (-0.02), AGIO: 87.20 (+0.33), CELG: 108.53 (+0.28)

Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 87.20 (+0.33)

Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 116.04 (-0.62), LNKD: 233.65 (+2.52), HAL: 52.40 (-0.83), AGIO: 87.20 (+0.33), IMPV: 45.11 (+0.46)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 105.20 (-1.70), CLVS: 59.02 (+0.58), ARWR: 6.53 (unch), ACHN: 14.28 (-0.57), MRK: 59.89 (+0.58), RTRX: 11.87 (+0.31), RGLS: 18.00 (-1.62), EPZM: 23.73 (-0.15), AGIO: 87.20 (+0.33), RMTI: 11.15 (-0.09), ARNA: 4.84 (+0.14), KERX: 15.86 (+0.27)

Cramer's Lightning Round - Isis Pharmaceuticals Has The Best Pipeline (10/28/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Oct 29, 5:59AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday October 2 8. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "Isis got slammed, and (the selloff) was overdone. It has the best pipeline...
GS: 189.92 (-0.26), RICE: 25.80 (-0.41), ISIS: 52.74 (+1.66), CYBR: 39.20 (+5.50), GNC: 43.75 (-0.47), HAL: 52.40 (-0.83), AGIO: 87.20 (+0.33), FTNT: 27.30 (+0.14)

'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 48.19 (+0.03), RICE: 25.80 (-0.41), GS: 189.92 (-0.26), FEYE: 34.04 (+0.89), ISIS: 52.74 (+1.66), CYBR: 39.20 (+5.50), GNC: 43.75 (-0.47), HAL: 52.40 (-0.83), EOG: 96.73 (-0.83), AGIO: 87.20 (+0.33), FTNT: 27.30 (+0.14)

Jim Cramer's 'Mad Money' Recap: Winners in the Expectations Game
at The Street - Tue Oct 28, 7:26PM CDT
It's expectations, not the earnings, that determine the direction of a company's stock price, and several companies proved that today, Cramer says.
KSS: 56.05 (-1.86), FEYE: 34.04 (+0.89), CYBR: 39.20 (+5.50), FB: 74.89 (+0.17), GNC: 43.75 (-0.47), HAL: 52.40 (-0.83), AGCO: 44.72 (-0.13), BWLD: 163.37 (+0.37), MAS: 23.22 (+0.03), YHOO: 50.99 (+0.39), WHR: 175.74 (+0.53), VSI: 48.19 (+0.03), SAVE: 78.50 (+0.14), RICE: 25.80 (-0.41), GS: 189.92 (-0.26), PH: 128.55 (-0.02), ISIS: 52.74 (+1.66), CMI: 146.06 (-0.43), EOG: 96.73 (-0.83), AGIO: 87.20 (+0.33), TWTR: 43.18 (+0.64), FTNT: 27.30 (+0.14), BABA: 119.73 (+1.53)

Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 21.46 (+0.16), AGIO: 87.20 (+0.33), CELG: 108.53 (+0.28)

Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 53.53 (-0.48), NVAX: 5.30 (+0.06), AGIO: 87.20 (+0.33), SNY: 46.77 (+0.21), MNKD: 6.19 (+0.11), CELG: 108.53 (+0.28)

Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that it will host a conference call and live webcast on Friday, November 7, 2014, at 8:00 a.m. EST to report its third quarter 2014 financial results and discuss recent business activities.
AGIO: 87.20 (+0.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

53% of European Telecom Users Eye Provider Switch

Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...

Nutromics Welcomes Plaxco: Strategic Tech Leap Forward

Professor Plaxco’s Dynamic Role at Nutromics Some folks start their day with breakfast and coffee, but Nutromics is grabbing headlines by introducing Professor Kevin Plaxco as the new Chief Scientific Officer. This strategic shift, made public on September 7, 2026, signals Nutromics’ ambition to amplify its DNA-based sensing footprint. As they gear up to launch their...

Clover's RSV Combo Vaccine Shows Promise in Trials

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Hims & Hers Faces Class Action: Investors Beware

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

Creality Rolls Out K3, SPARKX i8 at IFA 2026

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...

Global Movement Urges Dr. Hak Ja Han's Release

Under the shadows of Manhattan's skyline, something more than a regular service took shape. The New Yorker Hotel hosted an impassioned gathering of the Family Federation for World Peace and Unification. These folks weren't just saying their prayers; they were making a call—loud and resonant—for the release of Dr. Hak Ja Han. The Power of Collective Voices Gathering in...

York Space Systems Faces Class Action Over Misleading IPO

York Space Systems Under the Legal Spotlight Ever get that feeling when something just doesn’t sit right? Like a burr under the saddle, York Space Systems is now grappling with a class action lawsuit that's throwing a heap of shade on its recent moves. What’s at play? Bronstein, Gewirtz & Grossman, LLC, a law firm that seems to have a nose for corporate messes, has...

ISO 45010: First Guidance for Menstruation, Menopause

Tackling Menstruation and Menopause in the Workplace Today, the International Organization for Standardization (ISO) has taken a bold step forward by launching ISO 45010—a groundbreaking standard aimed at addressing menstruation and menopause in the workplace. Millions endure these natural processes throughout their careers, yet structured policies to support them have...

Nuix Leverages AI for Transformative Legal Review

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...